Experimenta | Tera-1 | HEK-293 |
---|
| PI assayb | Annexin Vc | PI assayb | Annexin Vc |
---|
-5FC; -Transf. | 9.2 ± 2.3 | ND | 7.7 ± 1.5 | ND |
-5FC; no-RCD | 9.0 ± 1.7 | ND | 7.4 ± 1.7 | ND |
-5FC; mNUS-RCD | 8.8 ± 2.9 | ND | 7.8 ± 2.1 | ND |
-5FC; CMV-RCD | 9.9 ± 2.5 | ND | 8.2 ± 2.2 | ND |
+5FC; -Transf. | 9.4 ± 2.1 | 10.9 ± 3.3 | 7.4 ± 1.8 | 8.7 ± 2.3 |
+5FC; no-RCD | 9.1 ± 2.5 | 10.7 ± 2.6 | 7.7 ± 1.6 | 8.6 ± 2.9 |
+5FC; mNUS-RCD | 59.5 ± 6.4 | 59.1 ± 3.9 | 7.8 ± 1.7 | 8.4 ± 2.8 |
+5FC; CMV-RCD | 67.3 ± 7.5 | 64.9 ± 5.6 | 73.8 ± 11.3 | 75.5 ± 8.6 |
- aCell viability tests shown on this table were done 24 hours after application of 5FC. "-5FC" means "no 5FC was added", "+FC" marks experiments with the addition of 5FC to the medium. "-Transf.", "no-RCD", "mNUS-RCD" and "CMV-RCD" mean "no transfection", "transfection with no-RCD construct", "transfection with mNUS-RCD" and "transfection with CMV-RCD", accordingly.
- bPropidium iodide tests were done at least in quadruplicates. The data represent integral proportion of necrotic and apoptotic cells.
- cAnnexin V assay was performed for all the experiments with the addition of 5FC to the medium. Tests were done in triplicates. The data represent integral proportion of necrotic and apoptotic cells.